New combo therapy aims to tame multiple food allergies at once
NCT ID NCT03181009
First seen May 11, 2026 · Last updated May 15, 2026 · Updated 1 time
Summary
This study tested whether a drug called omalizumab can make oral immunotherapy (OIT) safer for people allergic to two or more foods. Sixty participants aged 2 to 25 received OIT for multiple allergens along with omalizumab. The goal was to see if this combination allows lower maintenance doses and reduces allergic reactions during treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sean N. Parker Center for Allergy and Asthma Research at Stanford
Mountain View, California, 94040, United States
-
UCLA
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.